• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, June 8, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS

Engineered immune cells battle acute leukaemia

Bioengineer by Bioengineer
March 21, 2013
in NEWS
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
The results of the trial — done in five patients with acute lymphoblastic leukaemia — are published in Science Translational Medicine1 and represent the latest success for a 'fringe' therapy in which a type of immune cell called T cells are extracted from a patient, genetically modified, and then reinfused back. In this case, the T cells were engineered to express a receptor for a protein on other immune cells, known as B cells, found in both healthy and cancerous tissue.
 
When reintroduced into the patients, the tricked T cells quickly homed in on their targets. “All of our patients very rapidly cleared the tumour,” says Michel Sadelain, a researcher at the Memorial Sloan-Kettering Cancer Center in New York and an author of the study. The treatment “worked much faster than we thought”.
 
The technique has already shown promise against chronic leukaemia, but there were doubts about whether it could take on the faster-growing acute lymphoblastic leukaemia, a tenacious disease that kills more than 60% of those afflicted.  
 
Carl June, an immunologist at the University of Pennsylvania in Philadelphia and a pioneer in engineering T cells to fight cancer, says that he is surprised that the method worked so well against such a swift-growing cancer. The next step, he says, is to move the technique out of the ‘boutique’ academic cancer centres that developed it and into multicentre clinical trials.
 
“What needs to be done is to convince oncologists and cancer biologists that this new kind of immunotherapy can work,” he says.
 
Extra hope
Oncologist Renier Brentjens, also at Memorial Sloan-Kettering Cancer Center, remembers the day that he had to tell one of the patients in the trial that the weeks of high-dose chemotherapy the 58-year-old man had endured had not worked after all. “It was painful to have that conversation,” says Brentjens. “He tells me now it was the worst news he has ever heard in his life.”
 
Another month in the hospital on intensive chemotherapy drugs did nothing to help. By the time the man started the trial, 70% of his bone marrow was tumour.
 
Brentjens, Sadelain and their colleagues then extracted T cells from the patient and engineered them to express a ‘chimeric antigen receptor’, or CAR, that would target cells expressing a protein called CD19. Because CD19 is found on both healthy and cancerous B cells, the engineered T cells were unable to discriminate between the two. However, patients can live without B cells.
 
By two weeks after the procedure, the patient was showing signs of improvement. The treatment had driven his cancer into remission — as it did for the other four patients in the trial — so he became eligible for a bone-marrow transplant. A hundred days later, he is doing well, says Brentjens. Four of the five patients were well enough to receive transplants; the remaining patient relapsed and was ineligible.
 
Pharmaceutical firms have tended to be wary of the CAR technique because it is technically challenging, must be personalized to the patient and faces an untested path to regulatory approval, says Steven Rosenberg, head of the tumour immunology section at the National Cancer Institute in Bethesda, Maryland.
 
But this seems to be changing. Rosenberg points to a collaboration formed in August last year between June's group and the drug giant Novartis, as well as the launch of several small CAR-focused biotechnology firms. And Sadelein says that he is an investigator on a trial with the Dana-Farber Cancer Institute in Boston, Massachusetts, to test whether the technique can be exported to other treatment centers, among other outcomes.
 
Brentjens, meanwhile, is happy to have his patients in fighting spirits again. “You see these people at their lowest low emotionally as well as physically,” he says. “And now you can tell they’re in better shape because they’re making fun of your tie again.”
 
Story source:
 
The above story is reprinted from materials provided by Nature News.
 
Tags: Engineered immune cellsimmune cells
Share12Tweet8Share2ShareShareShare2

Related Posts

Professor Laurence Hurst

Bath Professor given international award recognizing lifetime research achievements

June 8, 2023
Scientists Develop Inorganic Resins for Generating and Purifying Radium and Actinium

Scientists develop inorganic resins for generating and purifying radium and actinium

June 7, 2023

DNAmFitAge: Biological age indicator incorporating physical fitness

June 7, 2023

Despite major progress nationally, two mercury emissions hotspots remain

June 7, 2023
Please login to join discussion

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    41 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Deep sea surveys detect over five thousand new species in future mining hotspot

    35 shares
    Share 14 Tweet 9
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Bath Professor given international award recognizing lifetime research achievements

Scientists develop inorganic resins for generating and purifying radium and actinium

DNAmFitAge: Biological age indicator incorporating physical fitness

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 51 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In